Azitra Inc (AZTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Azitra Inc (AZTR) has a cash flow conversion efficiency ratio of -0.761x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($3.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AZTR stock market capitalisation for the company's overall valuation and market capitalisation.
Azitra Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Azitra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Azitra Inc stock quote for real-time trading data and today's change.
Azitra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Azitra Inc ranked by their cash flow conversion efficiency. Review AZTR free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WestKam Gold Corp
V:WKG
|
0.023x |
|
Aurora Investment Trust plc
LSE:ARR
|
0.004x |
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
LETUS CAPITAL ZY 1
F:7I4
|
0.000x |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
N/A |
|
Marvel Discovery Corp
V:MARV
|
0.000x |
|
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
|
0.000x |
|
Kane Biotech Inc
V:KNE
|
0.912x |
Annual Cash Flow Conversion Efficiency for Azitra Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Azitra Inc from 2021 to 2025. Also see balance sheet size of Azitra Inc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.80 Billion | $-11.22 Million | -0.003x | +99.83% |
| 2024-12-31 | $5.70 Million | $-10.18 Million | -1.787x | +29.29% |
| 2023-12-31 | $2.91 Million | $-7.36 Million | -2.527x | -1197.56% |
| 2022-12-31 | $-36.26 Million | $-8.35 Million | 0.230x | -26.46% |
| 2021-12-31 | $-25.77 Million | $-8.07 Million | 0.313x | -- |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more